E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 10/8/2009 in the Prospect News PIPE Daily.

New Issue: MedMira secures C$2 million placement of units with Andurja equity investment

By Jennifer Chiou

New York, Oct. 8 - MedMira Inc. said it will take in C$2 million in an equity investment from Andurja AG.

Under the terms of the placement, Lucerne, Switzerland-based Andurja will acquire 40 million equity units at C$0.05 per unit.

Each unit consists of one common share and one common share purchase warrant exercisable for a period of three years from the closing date.

Each warrant entitles Andurja to purchase one common share of MedMira at C$0.06 for the first year and at C$0.10 for the next two years.

Under the terms of the transaction, Andurja will become a 19.85% shareholder of MedMira. The company added that this could increase to 33.13% if all warrants are exercised.

Also, Andurja has the right to nominate one director to the board of MedMira.

The transaction is subject to a vote by disinterested shareholders via written consent. TSX approval is also required.

Andurja is a privately owned investment company that is wholly owned by Urs Meile. It is the controlling and majority shareholder of Vitest AG, MedMira's strategic partner leading business development initiatives for Europe and Africa.

MedMira, based in Halifax, N.S., manufactures and markets in vitro flow-through rapid diagnostic tests.

Issuer:MedMira Inc.
Issue:Units of one common share and one warrant
Amount:C$2 million
Price:C$0.05
Warrants:One warrant per unit
Warrant expiration:Three years
Warrant strike price:C$0.06 for first year; C$0.10 for next two years
Investor:Andurja AG
Announcement date:Oct. 8
Stock symbol:TSX Venture: MIR
Stock price:C$0.06 at close Oct. 8
Market capitalization:C$6.94 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.